TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9682182
Drug: Modafinil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (300 mg x 2) during sleep deprivation (N1)
Study: 9682182
Drug: Modafinil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (300 mg x 2) and Placebo during recovery and control nights (N2)
Study: 7878164
Drug: Caffeine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2.5 mg/kg bodyweight)
Study: 7878164
Drug: Smoking (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking (1.2 mg nicotine yield from cigarette with 8 cued puffs)
Study: 41543
Drug: Temazepam 15
Normalized name: temazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 15 mg (short-term study)
Study: 22882353
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol (300,000 IU in six divided doses over 3 months)
Study: 22882353
Drug: Intramuscular cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cholecalciferol (300,000 IU as a single injection)
Study: 17352284
Drug: Antiresorptive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive agents (bisphosphonates)
Study: 31855009
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy for Depression plus Brief Motivational Interviewing (CBT-D + BMI)
Study: 31855009
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy for Depression (CBT-D)
Study: 29794306
Drug: JNJ‐39439335 (2-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐39439335 (2-50 mg)
Study: 26651333
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (100 μg or 200 μg)/vilanterol 25 μg
Study: 26651333
Drug: Existing asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Existing asthma maintenance therapy
Study: 23725677
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g)
Study: 20948459
Drug: anterior injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: anterior injection followed by laser
Study: 20948459
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg triamcinolone acetonide anterior injection
Study: 20948459
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide posterior injection
Study: 20948459
Drug: posterior injection
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: posterior injection followed by laser
Study: 14983953
Drug: Threshold tPSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold tPSA of >= 4.0 ng/mL
Study: 14983953
Drug: Threshold tPSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold tPSA of >= 3.0 ng/mL combined with f/tPSA threshold of <= 18%
Study: 31701163
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo
Study: 2022158
Drug: Omeprazole, 10
Normalized name: Omeprazole, 10 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 10 mg every morning
Study: 8003642
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg every morning
Study: 1095098
Drug: 400 rads
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 rads twice weekly for four weeks
Study: 24089693
Drug: 1-week free
Normalized name: Free Cysteine
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-week free nicotine replacement therapy (NRT) with behavioural counselling
Study: 24089693
Drug: 2-week free
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week free nicotine replacement therapy (NRT) with behavioural counselling
Study: 19289640
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR of 2.5 to 3.0)
Study: 19289640
Drug: Aspirin (162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (162 mg once daily)
Study: 12171689
Drug: Oral supplement
Normalized name: Healios Oral Supplement Unflavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement containing glucosamine, amino acids, minerals, and antioxidants
Study: 12171689
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (12 individuals who did not take the supplement)
Study: 7919326
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose (500 mL of plasma)
Study: 7919326
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL of 5% human serum albumin)
Study: 3277494
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists in combination with diuretics
Study: 3277494
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose diuretic and calcium blocker
Study: 31914324
Drug: Doxazosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (8 mg/day)
Study: 7955823
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of lomefloxacin
Study: 7955823
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of lomefloxacin
Study: 30696483
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ixekizumab every 2 weeks (IXEQ2W)
Study: 28294430
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg etanercept (ETN) twice weekly
Study: 22779217
Drug: SRP combined
Normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP combined with 1.7% hydrogen peroxide gel (Perio Gel) using custom trays
Study: 21980827
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg/day)
Study: 17555327
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g of DNJ-enriched powder (12 mg of DNJ)
Study: 8209276
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by radiotherapy (arm B)
Study: 2563311
Drug: Prazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (mean dose, 5 mg per day)
Study: 2563311
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean dose, 133 mg per day)
Study: 19967563
Drug: Placebo (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (900 mg per day for 6 months)
Study: 8875514
Drug: Glutamine-supplemented total
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented total parenteral nutrition (GTPN) with 25 g crystalline L-glutamine per 24 h
Study: 8875514
Drug: Conventional total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional total parenteral nutrition (CTPN)
Study: 1411294
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g four times daily)
Study: 9887898
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicines (CHMs)
Study: 18419878
Drug: budesonide DPI-B
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide DPI-B 360 microg twice-daily (total daily dose 720 microg)
Study: 18419878
Drug: budesonide DPI-A
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide DPI-A 400 microg twice-daily (total daily dose 800 microg)
Study: 18419878
Drug: budesonide DPI-B
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide DPI-B 180 microg once daily (total daily dose 180 microg)
Study: 18419878
Drug: budesonide DPI-B
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide DPI-B 360 microg twice-daily
Study: 18419878
Drug: budesonide DPI-A
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide DPI-A 400 microg twice-daily
Study: 18419878
Drug: budesonide DPI-B
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide DPI-B 180 microg once daily
Study: 18419878
Drug: budesonide DPI-A
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide DPI-A 200 microg once daily
Study: 16965691
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with alanyl-glutamine dipeptide
Study: 12856155
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg recombinant human TSH (rhTSH) followed by 2 mCi (74 MBq) iodine-131
Study: 12856155
Drug: 2 mCi
Normalized name: Iobenguane I 123 2 MCI/1 ML Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mCi (74 MBq) iodine-131 administered after stopping thyroid hormones to become hypothyroid
Study: 1328365
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment based upon weight reduction and sodium restriction
Study: 3870293
Drug: Aclatonium napadisilate
Normalized name: mebhydrolin napadisylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclatonium napadisilate (TM-723) at a dose of 50 mg
Study: 3870293
Drug: Prostaglandine F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandine F2 alpha (PGF2 alpha) at a dose of 2 mg
Study: 30291013
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched volume, subcutaneous injection once a week)
Study: 24607553
Drug: etanercept (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: etanercept (0.4 mg/kg twice weekly × 4 weeks)
Study: 9431859
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg irbesartan once a day
Study: 8237833
Drug: Conventional antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiarrhythmic therapy
Study: 3800090
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% povidone-iodine (Betadine)
Study: 20860413
Drug: Colesevelam (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3.75 g/day)
Study: 17999256
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic drugs (various types)
Study: 31571445
Drug: Teneligliptin 20
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 20 mg once daily for 12 weeks
Study: 24344941
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once daily for 12 weeks
Study: 28255099
Drug: NT‐proBNP cut-off
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP cut-off of ≥125 ng/L
Study: 14962527
Drug: Best treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best treatment without hormones (non-HRT)
Study: 20056931
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (tPA)
Study: 8391063
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A (retinol palmitate, orally 300,000 IU daily for 12 months)
Study: 15513568
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A
Study: 27593794
Drug: Ultrasound-guided caudal
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided caudal epidural steroid injection
Study: 19924670
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg oral prednisolone for 10 days
Study: 16380544
Drug: 1.6 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg/d riboflavin for 12 weeks
Study: 1354225
Drug: Cetirizine, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 15 mg twice a day (6 patients)
Study: 6238133
Drug: DDAVP (vasopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (vasopressin derivative) administered for 10 days, 40 micrograms per day
Study: 26453645
Drug: EBV IgG
Normalized name: EBV-CTL
DrugBank: Tabelecleucel (DB17072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV IgG antibody levels
Study: 26453645
Drug: Cotinine levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotinine levels >25 ng/mL
Study: 23350967
Drug: ICD only
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD only treatment
Study: 21263058
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (1 mg/kg) and IV Fentanyl (1 μg/kg)
Study: 11895966
Drug: WRSS1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSS1 vaccine (3 x 10(3) CFU)
Study: 11895966
Drug: WRSS1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSS1 vaccine (3 x 10(4) CFU)
Study: 11895966
Drug: WRSS1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSS1 vaccine (3 x 10(5) CFU)
Study: 11895966
Drug: WRSS1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSS1 vaccine (3 x 10(6) CFU)
Study: 11895966
Drug: WRSS1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRSS1 vaccine (all groups)
Study: 7872318
Drug: Higher dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dialysis efficacy (Kt/V urea and nPCR of 1.28 and 1.22 g/kg/d)
Study: 645142
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glibenclamide daily
Study: 645142
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet therapy
Study: 29578103
Drug: Bronchodilator (BD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator (BD; ipratropium 0.5mg + salbutamol 2.5 mg)
Study: 26514352
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation
Study: 20601671
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no EPO treatment)
Study: 11401877
Drug: Glycophosphopeptical (Inmunoferón)
Normalized name: glicofosfopeptical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycophosphopeptical (Inmunoferón) at oral doses of 3 g/d for 90 days
Study: 9184521
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug use history among homeless men in Baltimore
Study: 9184521
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug use history among homeless men in Boston
Study: 9184521
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug use history among homeless women in Baltimore
Study: 9184521
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug use history among homeless women in Boston
Study: 11685055
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous serum as a tear substitute
Study: 11685055
Drug: Unpreserved normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpreserved normal saline solution as a placebo
Study: 9742917
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus early postoperative intraperitoneal chemotherapy (mitomycin C on day 1 and 5-fluorouracil on days 2-5)
Study: 9742917
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus early postoperative intraperitoneal chemotherapy
Study: 7799589
Drug: Endolymphatic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endolymphatic injection of gentamycin and myelopid
Study: 23325582
Drug: Panitumumab treatment
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab treatment
Study: 21508863
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose of hydroxyzine 50 mg
Study: 21508863
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of hydroxyzine 50 mg
Study: 18225471
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group with nurse arm and one in-home session following trial completion at 6-months
Study: 14985185
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (WPI) supplementation (0.8 or 1.6 g/kg body mass)
Study: 29114095
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy (intravenous thrombolysis plus MT)
Study: 23922184
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with non‐ablative fractional laser and optimized intense pulsed light (Group A)
Study: 17883994
Drug: Nonpharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic therapy including cardiac resynchronization therapy, left ventricular assist devices, and cardiac rehabilitation
Study: 17883994
Drug: Interventions aimed
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventions aimed at treatment of acute HF syndromes
Study: 15248853
Drug: Anti-IgE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IgE treatment
Study: 10396235
Drug: Microimmunofluorescence test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microimmunofluorescence test (MIF) for IgG, IgM, and IgA antibodies to C pneumoniae
Study: 6338993
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine gel with St Mark's Hospital anal dilator
Study: 31799782
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg/day)
Study: 21392601
Drug: Local infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infusion of abciximab after aspiration with a 6F Export Aspiration Catheter
Study: 21392601
Drug: Local infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infusion of abciximab and no aspiration
Study: 21392601
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local infusion of abciximab and aspiration with a 6F Export Aspiration Catheter
Study: 21392601
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local infusion of abciximab and no aspiration
Study: 22216509
Drug: Metoprolol (75-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (75-300 mg) in combination with chlorthalidone
Study: 22216509
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with chlorthalidone
Study: 29709447
Drug: Quadrivalent Inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent Inactivated Vaccine (QIV)
Study: 14577025
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (Placebo)
Study: 9356529
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (900 mL/d)
Study: 9356529
Drug: Control (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (900 mL mineral water/d)
Study: 155891
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium and salbutamol
Study: 25622681
Drug: Intranasal lignocaine/phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal lignocaine/phenylephrine
Study: 16481389
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at a starting dose of 1.25 mg.m(‐2) with individual dose adjustment, administered intravenously on days 1‐5, every 21 days, for up to six courses.
Study: 8263310
Drug: l-fenfluramine
Normalized name: DL-Fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-fenfluramine
Study: 3906545
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus intravenous piperacillin
Study: 3906545
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic treatment (flucloxacillin plus tobramycin)
Study: 17637608
Drug: Drug-naive controls
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-naive controls
Study: 16177613
Drug: Trained limb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trained limb agonist EMG activation
Study: 12680882
Drug: Captopril 3
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril 3 x 25 mg day-1
Study: 10535657
Drug: ST (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST (standard treatment)
Study: 8735864
Drug: Thiorphan (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiorphan (1.25 mg/mL, 0.5 mL)
Study: 21840137
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 40 mg/m(2), six cycles